Danielle Gilliam on FDA’s Approval of Wegovy Pill from Novo Nordisk
Danielle Gilliam, Executive Medical Science Liaison Cardiovascular and Renal at Novo Nordisk North America, shared on LinkedIn:
”The FDA’s approval also clears the pill for use to reduce the risk of major cardiovascular events, such as death, heart attack or stroke, in adults with obesity and established cardiovascular disease, according to Novo Nordisk.”
Find more here.
Read the full announcement by Novo Nordisk here.
Novo Nordisk announced that the US Food and Drug Administration has approved the Wegovy pill, a once-daily oral semaglutide 25 mg, for long-term weight reduction and maintenance, as well as for reducing the risk of major adverse cardiovascular events.
The oral formulation is indicated for adults with obesity or overweight who have at least one weight-related comorbidity, and for adults with established heart disease to lower the risk of death, heart attack, or stroke.
In addition, Wegovy injection is approved for chronic weight management in paediatric patients aged 12 years and older.
The injectable form is also approved for the treatment of MASH in adults with moderate to advanced liver fibrosis, excluding those with cirrhosis.
Stay updated with Hemostasis Today.
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes
-
Apr 12, 2026, 17:30Flora Peyvandi: ABB Milan Presentations During the ISTH 2026
-
Apr 12, 2026, 17:01Hafiz Saad Ullah: Introducing to Fully Automatic Peripheral Blood Smear Stainer
-
Apr 12, 2026, 16:53Najmul Hasan Forhad: A Simple Framework for Mastering Anticoagulant Therapy
-
Apr 12, 2026, 16:36Piotr Czempik: Patient Blood Management Means Safer Care, Better Quality, and Responsible Resource Use
-
Apr 12, 2026, 16:31Eishi Asano: Available Evidence and Unmet Needs in EEG Use During Stroke Management